Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: As literature suggests that Early-Onset Alzheimer's Disease (EOAD) and late-onset AD may differ in important ways, need exists for randomized clinical trials for treatments tailored to EOAD. Accurately measuring reliable cognitive change in individual patients with EOAD will have great value for these trials.
Objectives: The current study sought to characterize and validate 12-month reliable change from the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) neuropsychological battery.
Design: Standardized regression-based (SRB) prediction equations were developed from age-matched cognitively intact participants within LEADS, and applied to clinically impaired participants from LEADS.
Setting: Participants were recruited from outpatient academic medical centers.
Participants: Participants were enrolled in LEADS and diagnosed with amyloid-positive EOAD (n = 189) and amyloid-negative early-onset cognitive impairment not related to AD (EOnonAD; n = 43).
Measurement: 12-month reliable change (Z-scores) was compared between groups across cognitive domain composites, and distributions of individual participant trajectories were examined. Prediction of Z-scores by common AD biomarkers was also considered.
Results: Both EOAD and EOnonAD displayed significantly lower 12-month follow-up scores than were predicted based on SRB equations, with declines more pronounced for EOAD across several domains. AD biomarkers of cerebral β-amyloid, tau, and EOAD-specific atrophy were predictive of 12-month change scores.
Conclusions: The current results support including EOAD patients in longitudinal clinical trials, and generate evidence of validation for using 12-month reliable cognitive change as a clinical outcome metric in clinical trials in EOAD cohorts like LEADS. Doing so will enhance the success of EOAD trials and permit a better understanding of individual responses to treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954665 | PMC |
| http://dx.doi.org/10.1016/j.tjpad.2025.100075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Ultrasound screening for abdominal aortic aneurysm (AAA) in primary care in a rural population].
Aten Primaria
September 2025
Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, España.
Objective: To assess the feasibility of implementing ultrasound screening for abdominal aortic aneurysm (AAA) in primary care by examining the prevalence of AAA and associated risk factors in northern Lleida, where no prior data exist and cases are detected opportunistically.
Design: Cross-sectional retrospective prevalence study derived from a pilot implementation of ultrasound AAA screening as a routine complementary test in six rural primary care centres over a 12-month period (March 2022 - March 2023).
Setting: Northern area of the province of Lleida, specifically the regions of Alt Urgell, Pallars Sobirà, Pallars Jussà and Alta Ribagorça.
Case Report: Multi-cancer early detection utilizing blood-based genomics: Single-institution case series of novel cancer screening.
Front Oncol
August 2025
Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, United States.
Purpose/objectives: Cancer screening continues to be a major challenge, with reliable tests only being available for very few cancers. Multi-cancer early detection (MCED) genomic tests are being developed that allow for blood-based screening of multiple cancers simultaneously. The PATHFINDER study was a multi-institution prospective cohort study in healthy participants over the age of 50 years (no cancer history, or history of treated cancer > 3 years prior), investigating the feasibility of the Galleri (GRAIL, LLC) cfDNA methylation MCED blood test.
View Article and Find Full Text PDFMedial Thigh Lift with Tumescent Local Anesthesia: Advancing Outpatient Body Contouring.
J Clin Med
August 2025
Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
: Demand for anesthesia-sparing body contouring techniques is rising. This study assessed the feasibility, safety, and outcomes of medial thigh lift performed exclusively under tumescent local anesthesia (TLA) in an outpatient setting. : A retrospective review was conducted that included 43 female patients (mean age of 41.
View Article and Find Full Text PDFMorphological and Functional Analysis of Residual Lung After Pneumonectomy in Lung Cancer Surgery via 3D-CT Method.
Life (Basel)
August 2025
Department of Thoracic Surgery, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey.
Pneumonectomy is a major surgical option for non-small cell lung cancer (NSCLC). This study evaluates the predictive value of three-dimensional computed tomography (3D-CT)-based lung volume analysis for postoperative function and explores its potential role in preoperative planning, risk assessment, and surgical decision-making. We evaluated 59 NSCLC patients who underwent pneumonectomy.
View Article and Find Full Text PDFPrediction of 1-Year Activity in Systemic Lupus Erythematosus: Hierarchical Machine Learning Approach.
JMIR Form Res
August 2025
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli, 8, Rome, 00168, Italy.
Background: Systemic lupus erythematosus (SLE) is a chronic disease characterized by a broad spectrum of involved organs, including neurological, renal, and vascular domains, with disease activity manifesting through unpredictable patterns that vary across individuals and over time, making the prediction of activity events particularly challenging.
Objective: This paper proposes a hierarchical machine learning model to predict a 12-month SLE activity, defined as the occurrence of at least one event among SLE hospitalization, new organ-involved domain, and neurological, renal, or vascular manifestation within the following year. At each patient's visit, the model considers all the features at the current time point, the information about the patient's clinical history, and about its last 12 months, to predict the outcome for the next 12 months.